Niels van Royen
@NielsRoyen
Followers
157
Following
30
Statuses
44
Interventional Cardiologist Head of Department Radboud University, Nijmegen the Netherlands
Joined November 2018
You can now apply for the summer course: An Introduction to the Fascinating World of Cardiology More information:
0
0
1
RT @RickVolleberg: 🆕 primary results of PECTUS-obs @JAMACardio Presence of high-risk plaques in FFR-negative nonculprit lesions is associ…
0
8
0
Hemodynamic transvalvular measurements to assess (para)valvular leakage during TAVI; simple, fast and cheap!
0
2
1
@JimDwyerMD @Radboud_Uni Great coverage of our Artica trial. Hope the results will help diminish pressure on EDs worldwide and improve decision making in patients presenting with chest discomfort
0
0
1
RT @CardiologyToday: ICYMI: "Implementation of this strategy can alleviate pressure on emergency departments which have to deal with seriou…
0
1
0
RT @aarts_joris: Results of the ARTICA randomized trial have been published in the European Heart Journal! Pre-hospital rule-out of ACS wit…
0
5
0
@CMichaelGibson What a shock! He turned the world of interventional cardiology upside down, telling us to treat non-culprit lesions in stemi which is now guideline practice
0
0
1
@PabloJ @krychtiukmd @Ana_Viana_T @proftomquinn @RosselloXavier @DFCapodanno @JGrapsa @secardiologia @AlbertAriza3 @Auribarri Yes, indeed unsettled issue in the guidelines. In COACT median time to cag was >100 hrs and performed in less than 2/3. Thus, a selective delayed strategy could be advocated. However, already a major change from recommendation to perform immediate angio and new RCTs soon there!
0
0
2
@DFCapodanno Sorry, this was my 1 year old daughter, no idea what she is trying to say... But I agree that we should not forget about our CV research, still many discoveries ahead of us
0
0
3
@THillMD @kerrigjl @perc_surgeon @AshishPershad @esbrilakis @JAG24851 @cghanratty @kevinjamescroce @jamescspratt @RinfretStephane @mbmcentegart @CAThompson99 @HadyLichaaMD This was the rationale behind the randomized EXPLORE trial, which was negative. So NC revasc is beneficial but apparently not in case of CTO and not in shock (culprit shock trial).
1
0
0
@RNijveldt @JuanSanchisFor Great to have yet another country on board for iModern, aiming to answer what is the optimal timing for NC revascularization in STEMI
0
0
0
RT @RNijveldt: First inclusion for the #iMODERN in Spain, thanks to @JuanSanchisFor and team! Congratulations!
0
5
0
@TroelsThim @RNijveldt @HRadboudumc I like that one! And that’s what we did. Trying to define optimal timing for NC treatment in the iModern trial.
0
0
1
@Guusdewaard @CardioTamara @RNijveldt @HRadboudumc @NWvanderHoeven @GreggWStone @rallamee @jerd10 Interesting thought! FFR just above threshold or iFR just below threshold in combination with large MI should make you cautious. One week waiting time enough?
1
0
0
@CardioTamara @RNijveldt @HRadboudumc Unfortunately not acceptable anymore since Complete (and Cvlprit, Compare, Prami etc). Other suggestions? @NWvanderHoeven @GreggWStone @Guusdewaard @rallamee @jerd10
1
0
2
@YongcheolKim2 @billgogas Thanks a lot, it was an outstanding ENCORE meeting and great to be with friends!
0
0
2
RT @HRadboudumc: Great honor to host the second International #Summer school on Cardiology, as organized by #RAMS at #Radboud #University.…
0
3
0
RT @RNijveldt: Yes! As from today our website is open, providing study info, enrollment numbers and useful links for downloads #iMODERN…
0
5
0
Great suggestion, just like ORBITA did. For me important messages; focus on prevention neuro damage and randomised trials remain highest class of evidence (40% “benefit” in observational studies).
@GreggWStone @zaidiskandar85 @HighSTEACS @drandrewsharp @jonnywatt @yadersandoval @NielsRoyen @SukhNijjer @mmamas1973 @dirkwestermann Agreed. An atlas of lesions seen / left / treated in the COACT trial would be an interesting paper.
0
0
1